The downgrade by a major financial institution like Goldman Sachs can significantly impact investor sentiment towards Pacific Biosciences, likely leading to a short-term decrease in stock price. The substantial reduction in the price target further emphasizes a bearish outlook on the stock, influencing market perception and potentially leading to a sell-off.